VC-backed Juno Therapeutics taps mutual funds in $134 mln funding
Juno Therapeutics, a Seattle-based biotech company focused on developing immunotherapies for cancer, has raised $134 million in its Series B funding.
6 August 2014•1 min read
Juno Therapeutics, a Seattle-based biotech company focused on developing immunotherapies for cancer, has raised $134 million in its Series B funding.
